Journals / Molecular Imaging and Radionuclide Therapy / 2014 / Cilt: 23 - Sayı: 1

Özofagus kanserli hastalarda 18f-fdg PET/BT ile ölçülen metabolik tümör hacminin prognostik önemi

Prognostic value of metabolic tumor volume measured by 18f-fdg PET/CT in esophageal cancer patients

Pages
12–15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients who have higher preoperative metabolic tumor volumes could be good candidates for more aggressive chemo-radiation therapy regiments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we aimed to explore prognostic importance of definition of preoperative metabolic tumor volume in esophageal cancer patients.
📊
Key Findings & Data:Methods: 22 patients who have histologically proven stage IIA-III esophageal cancer and underwent 18F-FDG PET/CT for preoperative staging of disease were included to the study.
💡
Conclusion & Impact:Patients who have higher preoperative metabolic tumor volumes could be good candidates for more aggressive chemo-radiation therapy regiments.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we aimed to explore prognostic importance of definition of preoperative metabolic tumor volume in esophageal cancer patients. Methods: 22 patients who have histologically proven stage IIA-III esophageal cancer and underwent 18F-FDG PET/CT for preoperative staging of disease were included to the study. After 18F-FDG PET/CT, all the patients underwent surgery within 4 weeks period. Patients have been followed up until death or Sept 15th, 2012. Dates of death were recorded for survival analysis. During evaluation of 18F-FDG PET/CT images, metabolic tumor volumes were calculated by drawing the isocontour region of interests from all visually positive FGD uptake lesions. Results: 22 patients (15M, 7F; mean age: 65.1±8.4, min-max:48-80) underwent 18F-FDG PET/CT for preoperative staging of esophageal cancer. Preoperative diagnosis was squamous cell and adeno cancer in 17 (%77) and 5 (%23) patients, respectively. Location of primary tumor is distal, proximal and mid-esophagus in 13 (%59), 6 (%27) and 3 (%13) patients, respectively. Primary tumor of all the patients were FDG avid (mean SUVmax: 18.85±7.0; range: 5.5-35.1). Additionally, 18F-FDG uptake was seen in mediastinal lymph nodes in 13 patients (5.45±8.15; range: 2.6-29.9). Mean metabolic tumor volumes of primary esophageal lesions were calculated as 8.77±8.46cm3 (range: 2.3-34.2). Mean MTV of lymph nodes was 2.44±1.01cm3 (range: 0.4-3.6). Mean total metabolic tumor volume was calculated as 9.99±8.58cm3 (range: 2.3-27.3). 10 patients died during 447±121 days follow-up period. Mean survival time was 11.9±1.5 months (95%CI: 8.99-14.74) for entire patient group. Total metabolic tumor volume had a significant effect on survival (p=0.045) according to Cox proportional hazards regression analysis. One unit increase in MTV caused 1.1 (95%CI:1.003-1.196) fold increase in hazard, at any time. Conclusion: Definition of preoperative metabolic tumor volume has a prognostic value in the prediction of postoperative survival times. Patients who have higher preoperative metabolic tumor volumes could be good candidates for more aggressive chemo-radiation therapy regiments.

Özet

Amaç: Bu çalışmada özofageal kanserli hastalarda preoperatif metabolik tümör volümü hesaplanmasının prognostik önemini araştırmayı amaçladık. Yöntemler: Çalışmaya histopatolojik olarak doğrulanmış ve preoperatif evreleme amacı ile 18F-FDG PET/BT uygulanmış evre IIA- III özofagus kanserli 22 hasta dahil edildi. 18F-FDG PET/BT’den sonra tüm hastalara 4 haftalık periyod içerisinde cerrahi girişim uygulandı. Hastalar ölüme ya da çalışmanın sonlandırıldığı 15 Eylül 2012 tarihine kadar takip edildi. Ölüm tarihleri sağkalım analizinde kullanılmak üzere kaydedildi. 18F-FDG PET/BT görüntülerinin değerlendirilmesi sırasında vizüel olarak FDG tutulumu gösteren tüm lezyonların çevresinden izokontur ilgi alanları çizilerek metabolik tümör volümü hesaplandı. Bulgular: Toplam 22 hastaya (15K, 7E; ort. yaş:65,1±8,4, min-maks:48-80) özofageal kanserin preoperatif evrelemesi amacı ile 18 F-FDG PET/BT yapıldı. 17 (%77) hastanın preoperatif tanısı yassı hücreli kanser iken, 5 (%23) hastanınki adenokanserdi. Tümör lokalizasyonları sırası ile 13 (%59), 6 (%27) ve 3 (%13) hastada distal, proksimal ve orta özofagustu. Tüm hastaların primer tümörlerinde FDG tutulumu izlendi (ort SUVmax: 18,85±7,0; min-maks: 5,5-35,1). Ek olarak, 13 hastada mediastinal lenf nodlarında (ort SUVmax: 5,45±8,15; min-maks: 2,6-29,9) FDG tutulumu saptandı. Özofageal lezyonların ortalama metabolik tümör volümü (MTV) 8,77±8,46cm3 (min-maks: 2,3-34,2) olarak hesaplandı. Lenf nodlarının ortalama MTV’si 2,44±1,01cm3 (min-maks:0,4-3,6) idi. Toplam ortalama metabolik tümör volümü 9,99±8,58cm3 (min-maks:2,3-27,3) olarak hesaplandı. 447±121 günlük takip süresinde 10 hasta exitus oldu. Tüm hasta grubunda ortalama sağkalım süresi 11,9±1,5 (95%CI:8,99-14,74) aydı. Cox hazard regresyon analizine göre toplam metabolik tümör volümü sağkalım üzerine anlamlı bir etkiye sahipti (p=0,045). MTV’de bir birimlik artış, risk oranında 1,1 kat (95%CI:1,003-1,196) artışa sebep olmaktaydı. Sonuç: Preoperatif metabolik tümör volümünün hesaplanması postoperatif sağkalım süresini öngörmede prognostik bir değere sahiptir. Bu nedenle daha yüksek preoperatif metabolik tümör volümüne sahip hastalar, daha agresif kemo-radioterapi rejimleri için iyi adaylar olabilirler.

🔖

Cite This Article

SOYDAL, Ç., YÜKSEL, C., KÜÇÜK, Ö. N., ÖKTEN, İ., ÖZKAN, E., ERDOĞAN, B. D. (2014). Özofagus kanserli hastalarda 18f-fdg PET/BT ile ölçülen metabolik tümör hacminin prognostik önemi. Molecular Imaging and Radionuclide Therapy, Cilt: 23 - Sayı: 1, 12–15. https://ajindex.com/articles/295185

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ferlay J, Shin HR, Bray F Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010:127;2893-2917
  2. Stavrou EP McElroy HJ, Baker DF Smith G, Bishop JF Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005. Med J Aust 2009:191;310-314
  3. I HS, Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med 2012;37:442- 446
  4. Hyun SH, Choi JY Shim YM, Kim K, Lee SJ, Cho YS, Lee JY Lee KH, Kim BT. Prognostic value of metabolic tumor volume measured by 18 F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010;17:115-122
  5. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353-359
  6. Chen MK, Chen TH, Liu JP Chang CC, Chie WC. Better prediction, of prognosis for patients with nasopharyngeal carcinoma using primary tumor volume. Cancer 2004;100:2160-2166
  7. Chen MK, Chen TH, Liu JP Chang CC, Chie WC. Metabolic tumor, burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007;69:328-333
  8. Kuwano H, Sumiyoshi K, Sonoda K, Kitamura K, Tsutsui S, Toh Y Kitamura M, Sugimachi K. Relationship between preoperative, assessment of organ function and postoperative morbidity in patients with oesophageal cancer. Eur J Surg 1998;164:581-586
  9. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921-928
  10. Okada M, Murakami T, Kumano S, Kuwabara M, Shimono T, Hosono M, Shiozaki H. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med 2009;23:73-80
  11. Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol 2011;21:274-280
  12. Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Positron emission tomography-computed tomography in predicting